Becker's Healthcare December 30, 2025
From payer shifts to regulatory milestones, GLP-1 therapies for obesity and diabetes continued to reshape the healthcare landscape in December.
Here are six updates:
- Pfizer struck a $2 billion deal with YaoPharma to develop and commercialize a small-molecule GLP-1 receptor agonist in phase 1 development for chronic weight management. Pfizer paid $150 million upfront and could pay up to $1.935 billion in additional milestone payments. The company also plans to evaluate the therapy alongside its phase 2 GIPR antagonist.
- The FDA approved the first oral GLP-1 for weight loss Dec. 22. Novo Nordisk’s once-daily 25-milligram semaglutide pill — a version of Wegovy — was cleared to reduce body weight and lower cardiovascular risk. Launch is expected in early...
Today's Sponsors
Today's Sponsor